Drug Profile
Glycopyrrolate inhaled - Pearl Therapeutics
Alternative Names: GP MDI; PT-001; PT001 GPLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pearl Therapeutics
- Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Phase II Asthma
Most Recent Events
- 28 Mar 2023 No development reported - Phase-II/III for Asthma (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in USA (Inhalation)
- 23 Feb 2021 Glycopyrrolate inhaled is still in phase II/III trial for Asthma (In adolescents, In adults, In children, In the elderly, Treatment-experienced) in USA (Inhalation) (NCT03547466)
- 12 Sep 2019 Pearl Therapeutics completes a phase II/III trial in Asthma (In adolescents, In adults, In children, In the elderly, Treatment-experienced) in USA (Inhalation) (NCT03358147)